MiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) incombination with pembrolizumab in pts with malignant mesothelioma
Authors
Krebs, Matthew GCarter, Louise
Villa, Shaun
King, A
Massey, C
Lorens, J
Darlington, Emma
Fennell, D
Affiliation
Experimental Cancer Medicine Team, the Christie NHS Foundation Trust, The University of Manchester and the Christie NHS Foundation Trust, Manchester, UKIssue Date
2018
Metadata
Show full item recordCitation
Krebs M, Carter L, Villa S, King A, Massey C, Lorens J, et al. P2.06-09 MiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in pts with malignant mesothelioma. J Thorac Oncol. 2018;13(10):S745.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2018.08.1264Additional Links
https://dx.doi.org/10.1016/j.jtho.2018.08.1264Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2018.08.1264